Emergent Biosolutions Inc (EBS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Emergent Biosolutions Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 7.20 $ — 19% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 66.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.95 | 0.95 – 0.95 | 733 | -37.9% | 1 |
| 12/31/2027 | 0.91 | 0.91 – 0.91 | 892 | – | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.11 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.58 | – | 195 | -29.60 | -16.10 | -80 | -82 |
| 2025: Q1 | 1.19 | 588.30 | 222 | -26.00 | 30.60 | -11 | -15 |
| 2025: Q2 | -0.22 | – | 141 | -44.70 | -8.50 | 106 | 104 |
| 2025: Q3 | 0.91 | -56.10 | 231 | -21.30 | 22.20 | -2 | -6 |
| 2025: Q4 | -1.04 | – | 149 | -23.60 | -36.70 | 78 | 74 |
| 2026: Q1 | 0.12 | -89.90 | 156 | -29.70 | 4.40 | -34 | -36 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 489 | 106 | 52 | 1.05 | 53 | 596 | 970 |
| 2017 | 561 | 124 | 83 | 1.64 | 208 | 912 | 1,070 |
| 2018 | 782 | 90 | 63 | 1.22 | 42 | 1,011 | 2,229 |
| 2019 | 1,106 | 114 | 55 | 1.04 | 188 | 1,089 | 2,327 |
| 2020 | 1,577 | 439 | 306 | 5.68 | 537 | 1,447 | 2,883 |
| 2021 | 1,774 | 341 | 220 | 4.06 | 321 | 1,612 | 2,958 |
| 2022 | 1,118 | -170 | -212 | -4.22 | -34 | 1,388 | 3,166 |
| 2023 | 1,049 | -726 | -761 | -14.85 | -206 | 649 | 1,823 |
| 2024 | 1,044 | -109 | -191 | -3.60 | 59 | 483 | 1,390 |
| 2025 | 743 | 110 | 53 | 0.93 | 171 | 523 | 1,319 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Emergent BioSolutions Inc., ein Life-Sciences-Unternehmen, bietet Lösungen zur Vorsorge und Reaktion auf versehentliche, vorsätzliche und natürlich auftretende Bedrohungen der öffentlichen Gesundheit in den USA, Kanada und international an.
| Employees | 900 |
|---|---|
| Headquarters | Gaithersburg, MD |
| Address | 300 Professional Drive, 20879 Gaithersburg, United States |
| Phone | 240 631 3200 |
| Website | emergentbiosolutions.com |
| IPO Date | 15. Nov 2006 |
| ISIN | US29089Q1058 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph C. Papa Jr., M.B.A., R.Ph. | CEO, President & Director | 1956 |
| Richard S. Lindahl M.B.A. | Executive VP & CFO | 1964 |
| Coleen Glessner | Executive Vice President of Quality, Ethics & Compliance | 1971 |
| Paul A. Williams | Senior Vice President of Products Business | 1967 |
| Simon C. Lowry M.D. | Chief Medical Officer and Head of Research & Development | 1973 |
| Jessica Perl | Senior VP, Corporate Secretary & General Counsel | 1981 |
| Michelle Pepin | Senior VP & Chief Human Resource Officer | – |
| Stephanie Duatschek | Chief Global Strategy & Franchise Development Officer | – |
| William Hartzel | Senior Vice President of Manufacturing & Bioservices | 1978 |
| Frank Vargo | VP & Treasurer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.